
I was diagnosed with ER/PR+ HER- primary breast cancer in February 2022. I was treated with a lumpectomy followed by 12 sessions of chemotherapy and 24 sessions of radiotherapy; I
I was diagnosed with ER/PR+ HER- primary breast cancer in February 2022. I was treated with a lumpectomy followed by 12 sessions of chemotherapy and 24 sessions of radiotherapy; I
A cancer drug which received standing ovation from the Global Medical Community is being withheld from NHS breast cancer patients. METUPUK are devastated by NICE decision not to recommend the drug
Emma Lawrence (née Fisher) 21.01.81 – 13.07.24 Everyone at METUPUK is incredibly saddened to hear that Emma Lawrence (née Fisher) has died at the age of 43. Emma was diagnosed
METUPUK members have done amazing things in the last two years and continue to do so. Here is an update on the last two months: Founder Jo Taylor was due
At the End of May 2024 Madeleine attended an event at the offices of the Economist on Pioneering person-centred breast cancer care. This event was part of a wider project looking at
I was diagnosed with hormone positive primary breast cancer in February 2022. I had a lumpectomy, chemotherapy, radiotherapy and am now on 10 years of reduce risking hormone repressing therapy.
Last Autumn, Jo Taylor founder of After Breast Cancer Diagnosis and METUPUK and Eva Schumacher from Mamma Mia, an online German cancer magazine, (Eva is a patient living with MBC),
We are heartbroken to share the news that Tassia Haines has died. A member of METUPUK and our Executive Lead for Wales, Tass had been a significant campaigner for MBC
METUPUK are disappointed by the National Institute of Clinical Excellence (NICE) decision to not recommend talazoparib (Talzenna ®, Pfizer Ltd.) for treating HER2-negative, locally advanced or metastatic breast cancer with
We met Emma as she applied to be one of the METUPUK Darker Side of Pink ladies with our campaign that started in 2021 which focused on metastatic breast cancer,